Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalisation among Finnish elderly and chronically ill—An interim analysis of a nationwide cohort study

<h4>Background</h4> In Finland, both mRNA and adenovirus vector (AdV) Covid-19 vaccines have been used after the vaccination campaign started on December 27, 2020. Vaccination of the elderly and chronically ill was prioritized and the interval between doses set to 12 weeks. The objective...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ulrike Baum, Eero Poukka, Arto A. Palmu, Heini Salo, Toni O. Lehtonen, Tuija Leino
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/2284407ed5d247d392f1066d8bb2b795
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2284407ed5d247d392f1066d8bb2b795
record_format	dspace
spelling	oai:doaj.org-article:2284407ed5d247d392f1066d8bb2b7952021-11-25T06:19:34ZEffectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalisation among Finnish elderly and chronically ill—An interim analysis of a nationwide cohort study1932-6203https://doaj.org/article/2284407ed5d247d392f1066d8bb2b7952021-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601574/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4> In Finland, both mRNA and adenovirus vector (AdV) Covid-19 vaccines have been used after the vaccination campaign started on December 27, 2020. Vaccination of the elderly and chronically ill was prioritized and the interval between doses set to 12 weeks. The objective of this interim analysis was to evaluate first and second dose vaccine effectiveness (VE) in a real-world setting. <h4>Methods</h4> During the first five months of the campaign, a register-based cohort study was conducted in the Finnish elderly aged 70+ years and those aged 16–69 years with medical conditions predisposing to severe Covid-19 (chronically ill). Using Cox regression, VE against SARS-CoV-2 infection and Covid-19 hospitalisation was estimated comparing the hazard in the vaccinated with that in the unvaccinated. <h4>Results</h4> The cohorts included 901092 elderly (89% vaccinated) and 774526 chronically ill (69% vaccinated) individuals. Three weeks after the first dose, mRNA VE against infection was 45% (95% confidence interval, 36–53%) and 40% (26–51%) in elderly and chronically ill; mRNA VE against hospitalisation was 63% (49–74%) and 82% (56–93%). In chronically ill, AdV VE was 42% (32–50) and 62% (42–75%) against infection and hospitalisation, respectively. One week after the second dose, mRNA VE against infection was 75% (65–82%) and 77% (65–85%) in elderly and chronically ill; mRNA VE against hospitalisation was 93% (70–98%) and 90% (29–99%). <h4>Conclusions</h4> Covid-19 vaccines protect against SARS-CoV-2 infection and Covid-19 hospitalisation. A single dose provides moderate protection in elderly and chronically ill, although two doses are clearly superior.Ulrike BaumEero PoukkaArto A. PalmuHeini SaloToni O. LehtonenTuija LeinoPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ulrike Baum Eero Poukka Arto A. Palmu Heini Salo Toni O. Lehtonen Tuija Leino Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalisation among Finnish elderly and chronically ill—An interim analysis of a nationwide cohort study
description	<h4>Background</h4> In Finland, both mRNA and adenovirus vector (AdV) Covid-19 vaccines have been used after the vaccination campaign started on December 27, 2020. Vaccination of the elderly and chronically ill was prioritized and the interval between doses set to 12 weeks. The objective of this interim analysis was to evaluate first and second dose vaccine effectiveness (VE) in a real-world setting. <h4>Methods</h4> During the first five months of the campaign, a register-based cohort study was conducted in the Finnish elderly aged 70+ years and those aged 16–69 years with medical conditions predisposing to severe Covid-19 (chronically ill). Using Cox regression, VE against SARS-CoV-2 infection and Covid-19 hospitalisation was estimated comparing the hazard in the vaccinated with that in the unvaccinated. <h4>Results</h4> The cohorts included 901092 elderly (89% vaccinated) and 774526 chronically ill (69% vaccinated) individuals. Three weeks after the first dose, mRNA VE against infection was 45% (95% confidence interval, 36–53%) and 40% (26–51%) in elderly and chronically ill; mRNA VE against hospitalisation was 63% (49–74%) and 82% (56–93%). In chronically ill, AdV VE was 42% (32–50) and 62% (42–75%) against infection and hospitalisation, respectively. One week after the second dose, mRNA VE against infection was 75% (65–82%) and 77% (65–85%) in elderly and chronically ill; mRNA VE against hospitalisation was 93% (70–98%) and 90% (29–99%). <h4>Conclusions</h4> Covid-19 vaccines protect against SARS-CoV-2 infection and Covid-19 hospitalisation. A single dose provides moderate protection in elderly and chronically ill, although two doses are clearly superior.
format	article
author	Ulrike Baum Eero Poukka Arto A. Palmu Heini Salo Toni O. Lehtonen Tuija Leino
author_facet	Ulrike Baum Eero Poukka Arto A. Palmu Heini Salo Toni O. Lehtonen Tuija Leino
author_sort	Ulrike Baum
title	Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalisation among Finnish elderly and chronically ill—An interim analysis of a nationwide cohort study
title_short	Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalisation among Finnish elderly and chronically ill—An interim analysis of a nationwide cohort study
title_full	Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalisation among Finnish elderly and chronically ill—An interim analysis of a nationwide cohort study
title_fullStr	Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalisation among Finnish elderly and chronically ill—An interim analysis of a nationwide cohort study
title_full_unstemmed	Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalisation among Finnish elderly and chronically ill—An interim analysis of a nationwide cohort study
title_sort	effectiveness of vaccination against sars-cov-2 infection and covid-19 hospitalisation among finnish elderly and chronically ill—an interim analysis of a nationwide cohort study
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/2284407ed5d247d392f1066d8bb2b795
work_keys_str_mv	AT ulrikebaum effectivenessofvaccinationagainstsarscov2infectionandcovid19hospitalisationamongfinnishelderlyandchronicallyillaninterimanalysisofanationwidecohortstudy AT eeropoukka effectivenessofvaccinationagainstsarscov2infectionandcovid19hospitalisationamongfinnishelderlyandchronicallyillaninterimanalysisofanationwidecohortstudy AT artoapalmu effectivenessofvaccinationagainstsarscov2infectionandcovid19hospitalisationamongfinnishelderlyandchronicallyillaninterimanalysisofanationwidecohortstudy AT heinisalo effectivenessofvaccinationagainstsarscov2infectionandcovid19hospitalisationamongfinnishelderlyandchronicallyillaninterimanalysisofanationwidecohortstudy AT toniolehtonen effectivenessofvaccinationagainstsarscov2infectionandcovid19hospitalisationamongfinnishelderlyandchronicallyillaninterimanalysisofanationwidecohortstudy AT tuijaleino effectivenessofvaccinationagainstsarscov2infectionandcovid19hospitalisationamongfinnishelderlyandchronicallyillaninterimanalysisofanationwidecohortstudy
_version_	1718413851049852928

Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalisation among Finnish elderly and chronically ill—An interim analysis of a nationwide cohort study

Ejemplares similares